AMA Update 127: The FDA on Molnupiravir and COVID-19: What physicians need to know, Part III
In part three of this three-part series, Aimee Hodowanec, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what physicians need to know about Molnupiravir as treatment for COVID-19.